Dr. Alessi-Severini received her undergraduate training (a degree in Pharmaceutical Chemistry and Technology and a degree in Pharmacy) at the University of Parma (Italy). She obtained her PhD in Pharmaceutical Sciences in 1993 from the University of Alberta (Canada) and completed her post-doctoral training in the Department of Pharmacology (Faculty of Medicine, University of Alberta) while receiving a fellowship from the Alberta Cancer Board.
Between 1996 and 2003, Dr. Alessi-Severini was extensively involved with the provincial drug review process as a consultant to Alberta Blue Cross and Manitoba Health while holding an Adjunct Professor appointment with the University of Alberta.
In 2002-2003 she represented the province of Manitoba on the Common Drug Review Committee before joining the University of Manitoba in 2003.
In the College of Pharmacy, Dr. Alessi-Severini coordinates the Electives Program and teaches in the areas of toxicology, pharmaceutical policy and pharmacoepidemiology.
Her research program includes studies on the utilization, safety and effectiveness of medications including psychotropic agents for the treatment of schizophrenia, depression and anxiety, and, more recently, antiviral agents for the treatment of hepatitis C.
Other research interests include patients’ perspective regarding smoking cessation interventions and therapies for Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder.
Dr. Alessi-Severini has been serving on provincial and national committees such the Manitoba Drug Standards and Therapeutics Committee, the Association of Faculties of Pharmacy of Canada, the Canadian Drug Expert Committee, the Pharmacy Examining Board of Canada, and the Women’s Health Research Foundation of Canada.
She is also a member of the Manitoba team of the Canadian Network for Observational Drug Effect Studies. Dr. Alessi-Severini is the recipient of the 2017 Leslie F. Buggey Professorship in Pharmacy.
Utilization, safety and effectiveness of medications used in the treatment of various conditions including schizophrenia, depression, anxiety, attention deficit hyperactivity disorder, autism, and hepatitis C. Additional research projects explore the use and effectiveness of smoking cessation agents, and patients’ perspective on the effectiveness of medications, vaccines and health services.
1993 Doctorate, Pharmaceutical Sciences, University of Alberta
1983 Bachelor's, Pharmacy, Universita’ degli Studi di Parma
1981 Bachelor's, Pharmaceutical Chemistry and Technology, Universita’ degli Studi di Parma
Hamad A, Alessi-Severini S, Mahmud S, Brownell M, Kuo I. “Early Childhood Antibiotics Exposure and the Risk of Autism Spectrum Disorders”. International Journal of Epidemiology 2018, 1–10 doi: 10.1093/ije/dyy162
Breik N, Kuo I, Bugden S, Moffat M, Alessi-Severini S. “Treating children with ASD: the perspective of caregivers” Journal of Pharmacy and Pharmaceutical Sciences 21, 74s – 87s, 2018
Brandt J, Alkabbani W, Alessi-Severini S, Leong C. “Translating Benzodiazepine Consumption Data into Meaningful Population Exposure: Integration of Two Metrics for Improved Reporting”. Clin Drug Investig doi.org/10.1007/s40261-018-0648-y
Biscontri RG, Jha S, Collins DM, Bugden S, Katz LY, Alessi-Severini S. “Movement disorders in children and adolescents receiving antipsychotic pharmacotherapy: a population-based study”. Journal of Child and Adolescent Psychopharmacology, 27(10):892-896, 2017 (doi: 10.1089/cap.2017.0036).
Leong C; Sareen, J; Leslie, LW, Enns, MW; Bolton, J; Alessi-Severini, S; Katz, L; Logsetty, S; Snider, C; Berry, J; Prior, HJ; Chateau, DM. “Validity of the Days Supply Field In Pharmacy Administrative Claims Data for the Identification of Blister Packaging of Medications" Pharmacoepidemiology and Drug Safety 26(12)1540-1545, 2017
Leong C, Raymond C, Chateau D, Dahl M, Alessi-Severini S, Falk J, Bugden S, Katz A. “Psychotropic Drug Use Before, During, and After Pregnancy: A population-based study in a Canadian cohort (2001-2013)” Canadian Journal of Psychiatry 62(8):543-550, 2017
Leong C, Alessi-Severini S, Enns MW, Sareen J, Bolton J, Prior HJ, Nie Y, Chateau D. “Cerebrovascular, Cardiovascular, and Mortality Events in New Users of SSRIs and SNRIs: a propensity score-matched population-based study” Journal of Clinical Psychopharmacology 37(3): 332-340, 2017
Phung A, Luo L, Breik N, Alessi-Severini S. “Use of smoking cessation products: a survey of patients of community pharmacies” Canadian Pharmacists Journal 150(5): 326–333, 2017
Leong C, Enns MW, Sareen J, Alessi-Severini S, Bolton J, Prior HJ, Chateau D. “New Antidepressant Use in Older Adults: A Canadian Population-based Study (1997-2013)” Aging and Mental Health 21(7), 720-729, 2017
Alessi-Severini S, Bolton JM, Enns MW, Dahl ME, Chateau D, Collins DM, Sareen J. “Sustained use of benzodiazepines and dose escalation in a Canadian population” Psychiatric Services in Advance (doi: 10.1176/appi.ps.201500380), 2016
Alessi-Severini S, Metge C, Kuo I. Eleven years of experience with the Electives Program at the College of Pharmacy, University of Manitoba, 2018 AFPC CPERC, Ottawa, ON, June 12-14, 2018 (oral presentation)
Hamad AF, Alessi-Severini S, Mahmud S, Brownell M and Kuo I. Prenatal Antibiotics Exposure and the Risk of Autism Spectrum Disorders: A Population-Based Cohort Study, 2018 AFPC CPERC, Ottawa, ON, June 12-14, 2018 (poster presentation)
Hamad AF, Alessi-Severini S, Mahmud S, Brownell M, Kuo I. Prenatal Antibiotics Exposure and the Risk of Autism Spectrum Disorders: A Population-Based Cohort Study, ISPE Mid-Year Meeting, Toronto, Canada, April 21-24, 2018 (poster presentation).
Hamad AF, Alessi-Severini S, Mahmud S, Brownell M, Kuo I, Prenatal Antibiotics Exposure and the Risk of Autism Spectrum Disorders: A Population-Based Cohort Study, The Society of Epidemiologic Research Conference, Baltimore (MD), 2018 (oral presentation)
Janzen D, Kuo I, Leong C, Bolton J, Alessi-Severini S. Initiation of long-acting injectable antipsychotics in Manitoba. Canadian Society for Epidemiology and Biostatistics 2018 National Student Conference, Thunder Bay, Canada, June 15-17, 2018 (oral presentation).
Janzen D, Kuo I, Leong C, Bugden S, Bolton J, Alessi-Severini S. Utilization of long-acting injectable antipsychotics in the Canadian province of Manitoba. ISPE Mid-Year Meeting, Toronto, Canada, April 21-24, 2018 (poster presentation).
Janzen D, Kuo I, Bugden S, Bolton J, Alessi-Severini S. Use of long-acting injectable antipsychotics in Manitoba. 2018 CADTH Symposium, Halifax, Canada, April 15-17, 2018 (poster presentation).
Alessi-Severini S. Use of psychotropic medications in the province of Manitoba. Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, March 28, 2018 (invited presentation to the Dean’s Grand Rounds)
For contact details, visit
the faculty directory.